{"Title":"Apellis Pharmaceuticals","Industry":"PHARMACEUTICAL PREPARATIONS","Employees":"28","Founded":"","Address":"","Phone":"(502) 241-4114","Web_address":"http://www.apellis.com","Market_cup":"$689.6mil","Revenues":"$0 mil (last 12 months)","Net_income":"$-35.0 mil (last 12 months)","Symbol":"APLS","Exchange":"NASDAQ","Shares":"10.7","Price_range":"$14.00 - $14.00","Est_volume":"$150.0 mil","Manager":"Citigroup/ J.P. Morgan/ Evercore ISI","CO_managers":"-","Exp_to_trade":"11/9/2017","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"We are a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. We believe that this approach can result in broad inhibition of the principal pathways of the complement system and has the potential to effectively control a broad array of complement-dependent autoimmune and inflammatory diseases."}